Close

Sandford D. Smith Appointed to Aegerion Pharmaceuticals' Board of Directors Dec 20, 2011 08:00AM
Genzyme Reports No Statistical Superiority Observed in Rebif Phase III (SNY) Dec 20, 2011 06:24AM
Genzyme Reports Top-line Results for TENERE Study of Oral Teriflunomide in Relapsing Multiple Sclerosis Dec 20, 2011 01:00AM
Biotech M&A Will Be In Focus in 2012 - Goldman Dec 15, 2011 11:41AM
Isis Pharma (ISIS) Reports Delay in KYNAMRO NDA Submission Dec 15, 2011 08:05AM
View Older Stories

Nov 16, 2011 08:30AM Genzyme and Cystic Fibrosis Foundation Therapeutics Announce Collaboration to Discover New CF Drugs
Nov 14, 2011 06:38AM Sanofi's (SNY) Genzyme Reports Alemtuzumab Phase III Met Both Primary Endpoints
Nov 14, 2011 01:00AM Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
Nov 10, 2011 08:23AM Genzyme Appoints Leaders for Multiple Sclerosis and Rare Disease Businesses
Nov 3, 2011 07:30AM Sanofi: Net sales up 10.1% and Business net income(1) up 4.1% at CER(2)
Nov 3, 2011 03:05AM Sanofi Video Q&A: CFO Jérôme Contamine Comments on Q3 2011 Results
Oct 24, 2011 10:31AM Sanofi (SNY) Promotes David Meeker to CEO of Genzyme
Oct 24, 2011 10:30AM Sanofi Appoints David Meeker Chief Executive Officer of Genzyme
Oct 24, 2011 06:53AM Sanofi (SNY), Genzyme Report Statistically Significant Improvement for Alemtuzumab in MS Patients
Oct 22, 2011 03:15AM Alemtuzumab (Lemtrada™*) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III Study
Jul 28, 2011 07:19AM Genzyme Submits NDA for Mipomersen to EMA; Select Kynamro as Brand Name (SNY) (ISIS)
Jul 12, 2011 07:21AM Sanofi (SNY) Reports Alemtuzumab Phase 3 Meets Primary Endpoint; Secondary Endpoint Not Statistically Significant
May 12, 2011 02:19PM Barclays on Global Pharmaceuticals: Global Therapeutic Conference Preview: Multiple Sclerosis
Apr 14, 2011 07:52AM Needham & Company Maintains a 'Hold' on ISIS Pharmaceuticals (ISIS); Pipeline Progress Review – Long-Term, Early Stage Programs Are Encouraging
Apr 7, 2011 09:11AM sanofi-aventis' (SNY) Genzyme to Present Alemtuzumab Phase 2 Data
Mar 29, 2011 05:21PM BlackRock (BLK) Replacing Genzyme (GENZ) in S&P 500
Mar 23, 2011 10:37AM Canaccord Genuity Morning Coffee on Merck & Co. (MRK) and Sanofi-Aventis (SNY): So Long, Farewell, Au Revoir
Mar 7, 2011 08:11AM Genzyme (GENZ) Board Unanimously Recommends Shareholders Approves Sanofi-Aventis (SNY)
Feb 18, 2011 05:32PM Top 10 News Items 2/14-2/18: NYSE Euronext/Deutsche Boerse Announces Definitive Agreement, Sanofi, Genzyme Finally Approve Deal, Stocks Continue Higher, Up 28% Since Sept.
Feb 18, 2011 10:00AM Jefferies Cuts Estimate & Raises Price Target on BioMarin Pharmaceutical (BMRN), Maintains Buy Rating
Feb 17, 2011 10:34AM Canaccord Genuity Morning Coffee on Sanofi-Aventis (SNY) and Genzyme (GENZ): An Extra $5 Will Help The Medicine Go Down
Feb 17, 2011 08:22AM Jefferies Downgrades Genzyme (GENZ) to Hold, Lowers EPS Estimates For FY11 & FY12
Feb 17, 2011 08:22AM Morgan Joseph Downgrades Genzyme (GENZ) to Hold; To be Acquired for $74 Plus CVRs
Feb 16, 2011 10:29AM Notable Mergers and Acquisitions of the Day 02/16: GENZ/SNY, BEE, ARG/APD
Feb 16, 2011 07:49AM Sanofi-aventis (SNY) volatility flat into acquisition of Genzyme for $74 per share in cash
Feb 16, 2011 06:44AM Genzyme (GENZ) Agrees To Be Acquired by Sanofi-aventis (SNY) for $20.1 Billion
Feb 15, 2011 12:01PM Genzyme (GENZ) Jumps On Reports Deal Reached at $74/Share Plus Rights
Feb 15, 2011 11:57AM Genzyme Corp. (GENZ) sees upside on news Sanofi-Aventis (SNY) deal could be announced soon
Feb 10, 2011 05:49PM Goldman Sachs (GS) Has 6.8% Stake in Genzyme (GENZ, SNY)
Feb 1, 2011 11:57AM Genzyme (GENZ) Dips On Sanofi Headlines
Feb 1, 2011 11:53AM Sanofi (SNY) talks said to value Genzyme (GENZ) at $76-$77/share with CVR fee -Bloomberg
Jan 31, 2011 08:37AM Genzyme (GENZ) Will Allow Sanofi-Aventis To Conduct Due Diligence
Jan 24, 2011 12:21PM This Hedge Fund Guru Profited Big-Time From the Buyout of Genoptix (GXDX), See What Other Targets He Is Buying
Jan 24, 2011 07:58AM Sanofi-aventis (SNY) Tenders 0.4% of Genzyme (GENZ); Extends Deadline
Jan 12, 2011 11:53AM Genzyme (GENZ) Shares Rise as Sanofi's (SNY) Proposed Bid Wins EU Antitrust Approval
Jan 10, 2011 08:17AM Genzyme (GENZ) Says Talks with Sanofi-Aventis (SNY) Continuing
Dec 21, 2010 11:58AM Genzyme (GENZ) Reportedly Open to Price In Sanofi (SNY) Takeover Battle
Dec 20, 2010 08:37AM Takeover Target Genzyme (GENZ) Has Meeting at 1PM ET
Dec 13, 2010 10:20AM Genzyme (GENZ) Board Reiterates Position Following sanofi (SNY) $69/Share Tender Results
Nov 30, 2010 08:38AM Ticonderoga Maintains a 'Neutral' on Evercore Partners (EVR); Dynegy Breakdown Highlights "Key Deal" Risk for EVR
Nov 26, 2010 09:13AM Genzyme (GENZ) Chief Termeer Affirms $69/Share Bid Offers No Starting Point for Discussions (SNY)
Nov 9, 2010 11:16AM Canaccord Genuity Maintains a 'Buy' on Amicus Therapeutics (FOLD); Rolling Out New Amigal Trials With GSK's Support
Nov 8, 2010 01:30PM Sanofi-aventis (SNY) Seeks Clarification from Genzyme (GENZ) Over Potential Board Actions
Oct 28, 2010 12:12PM sanofi-aventis (SNY) Expands Presence in China with $520.6M Acquisition of BMP Sunstone (BJGP)
Oct 22, 2010 11:37AM Genzyme (GENZ) Confirms Issues Discussed in Presentation This Morning: $89/Share Estimate, Q4, FY11 Outlook
Oct 22, 2010 10:53AM Genzyme (GENZ) Thinks its Worth $89/Share Based on Strong FY11 EPS View
Oct 8, 2010 10:31AM Notable Mergers and Acquisitions of the Day 10/08: ALEX, GENZ/SNY
Oct 7, 2010 04:44PM Genzyme's (GENZ) Board Unanimously Rejects Sanofi (SNY) Bid; Calls Offer 'Inadequate'
Oct 7, 2010 04:14PM Genzyme's (GENZ) Board Allowing Management, Advisors to Look at Alternatives to Sanofi's Hostile Bid -WSJ
Oct 4, 2010 11:35AM Sanofi's Pursuit of Genzyme (GENZ) Gets 'Hostile'; Higher Bid Seen
View Older Stories